FDA Drug Safety Podcast: FDA strengthens kidney warnings for diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR)
On June 14, 2016, FDA strengthened the existing warning about the risk of acute kidney injury for the type 2 diabetes medicines canagliflozin (brand names Invokana, Invokamet) and dapagliflozin (brand names Farxiga, Xigduo XR).
Source: FDA Drug Safety Podcasts - Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts
More News: Canagliflozin | Dapagliflozin | Diabetes | Diabetes Type 2 | Drugs & Pharmacology | Endocrinology | Food and Drug Administration (FDA) | Forxiga | Invokana | Podcasts | Urology & Nephrology | Warnings